Crossmark

Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours – a single centre experience

Crossref DOI link: https://doi.org/10.1007/s00259-025-07235-w

Published Online: 2025-03-26

Published Print: 2025-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kashyap, Raghava https://orcid.org/0000-0002-1007-974X
Alipour, Ramin

Boehm, Emma

Jewell, Kerry

RaviKumar, Aravind S.

Cardin, Anthony

Saghebi, Javad

Hofman, Michael S.

Fahey, Michael T.

Michael, Michael

Akhurst, Tim

Hicks, Rodney J.

Kong, Grace
Funding

Funding for this research was provided by:

University of Melbourne
License Information

Text and Data Mining valid from 2025-03-26

Version of Record valid from 2025-03-26
More Information

Article History

Received: 10 February 2025

Accepted: 18 March 2025

First Online: 26 March 2025

Declarations

:

: Not applicable.

: No direct conflicts of interests with the current research work.

Document is current

Any future updates will be listed below